为您找到相关结果约500个

你是不是要搜索 期刊骨髓增生异常综合征 Pd1 点击跳转

PD1-IL2v: A next generation, PD-1-targeted cytokine.

Selection of PD1/PD-L1 X-Aptamers

Basis of PD1/PD-L1 Therapies

Regulatory Effect of PD1/PD-Ligand 1 (PD-L1) on Treg Cells in Patients with Idiopathic Pulmonary Fibrosis

PD1/PD-L1 Axis in Uro-oncology

Inhibition of PD1:PD-L1 interaction by an E-coli-derived optimized PD1 variant

TARGETING PD1/PD-L1/PD-L2 SIGNALING IN ENDOMETRIOSIS

Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquiredresistance to IPI+PD1 immunotherapy

Nature and management of melanoma recurrences following adjuvant anti-PD-1 (PD1) therapy

Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse

FAK-PD1: a phase I/IIa trial of FAK (defactinib) & PD-1 (pembrolizumab) inhibition

PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation

PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm

Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma(MM) resistant to PD1 monotherapy.

为您找到相关结果约500个

共500条页码: 1/34页15条/页